Compare Natera Inc. Common Stock (NTRA) vs TTM Technologies Inc. Common Stock (TTMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs TTM Technologies Inc. Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while TTM Technologies Inc. Common Stock trades at $99.05 (market cap $12.22B). The key difference: Natera Inc. Common Stock is far larger — about 4.7× TTM Technologies Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, TTM Technologies Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and TTM Technologies Inc. Common Stock for 2 Days on average.
| NTRA | TTMI | |
|---|---|---|
Market Cap | $57.03B | $12.22B |
Volume | 1,131,157 | 3,732,329 |
Sector | Health | Technology |
52-Week High | $425.64 | $221.47 |
52-Week Low | $179.42 | $55.69 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $56.18B | $12.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TTMI trades at $116.10, up 5.23% today, but faces a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong revenue growth is projected, from $2.9B in 2025 to $3.4B in 2026, alongside a rising net profit margin. A significant $1.7B defense backlog and expansion in AI data-center demand support the growth narrative, though the stock's valuation multiples appear elevated.
The outlook is mixed; robust fundamentals and overwhelming analyst buy ratings (85.7%) suggest long-term potential, with a consensus price target of $203.67 implying substantial upside. However, near-term technical weakness and high valuation ratios relative to profitability metrics present risks, requiring careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About TTM Technologies Inc. Common Stock
TTM Technologies manufactures printed circuit boards, radio-frequency components, and electronics assemblies. Its products are used in aerospace, defense, automotive, data center, and communications equipment.
Read more on TTMI →
